CoChat
Cited by 44

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial

Tesser, John R. P., Crowley, Angela R., Box, Emily Jane, June, Joshua P., Wickersham, Pendleton Brewster, Valenzuela, Guillermo J., Gaylis, Norman B., Lam, Gordon K. W., Pacheco, Leroy A., Ridley, David J., Pinto-Patarroyo, Gineth Paola, Novack, Stuart N., Churchill, Melvin A., Kohler, Minna, Lee, Eric C., Pando, Jose A., Parris, Glenn R., Peterson, Jeff R., Shah, Tina, Singhal, Atul K., Vuong, Victoria, Levine, Yaakov A., Evangelista, Melissa L., Derosier, Amy A., Curtis, Jeffrey R., Richardson, R. Mark, Chernoff, David · 2026 · Nature Medicine

Abstract

The inflammatory reflex, in which vagus nerve signaling modulates cytokine production, is dysregulated in rheumatoid arthritis (RA). RESET-RA, a pivotal, double-blind, randomized, sham-controlled trial, evaluated a vagus nerve-targeted neuromodulation system for RA in 242 patients with inadequate response/intolerance to biological/targeted synthetic disease-modifying antirheumatic drugs. Patients were randomized to active or sham stimulation for 3 months, and then all received open-label stimulation with results reported to 12 months. The primary end point was 3-month American College of Rheumatology 20% (ACR20) response. ACR20 rates were higher with active simulation than with sham at 3 months (35.2% versus 24.2%, P = 0.0209), which further improved in open-label to 50.0% at 6 months and 52.8% at 12 months (all-completers). Adverse events occurred in a similar proportion of patients in both arms. Related serious adverse events (rate = 1.6%) were all perioperative, and resolved. Vagus nerve-mediated neuroimmune modulation for RA achieved its primary efficacy end point and produced durable clinical benefits with a favorable safety profile. ClinicalTrials.gov registration: NCT04539964 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-025-04114-7

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 39

  1. Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402, 2019–2033 (2023). · DOI · Paper page
  2. Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 73, 924–939 (2021). · DOI · Paper page
  3. Baker, M. C., Nagy, D., Tamang, S., Horvath-Puho, E. & Sorensen, H. T. Vagotomy and the incidence of rheumatoid arthritis and osteoarthritis: a Danish register-based study. Arthritis Res. Ther. 27, 106 (2025). · DOI
  4. Koopman, F. A. et al. Autonomic dysfunction precedes development of rheumatoid arthritis: a prospective cohort study. eBioMedicine 6, 231–237 (2016). · DOI
  5. Tracey, K. J. The inflammatory reflex. Nature 420, 853–859 (2002). · DOI · Paper page
  6. Chavan, S. S., Pavlov, V. A. & Tracey, K. J. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity 46, 927–942 (2017). · DOI · Paper page
  7. Pavlov, V. A. & Tracey, K. J. Bioelectronic medicine: preclinical insights and clinical advances. Neuron 110, 3627–3644 (2022). · DOI
  8. Dalli, J., Colas, R. A., Arnardottir, H. & Serhan, C. N. Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity 46, 92–105 (2017). · DOI · Paper page
  9. Genovese, M. C. et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol. 2, e527–e538 (2020). · DOI · Paper page
  10. Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, 8284–8289 (2016). · DOI · Paper page
  11. Gaylis, N. B. et al. Neuroimmune modulation for drug-refractory rheumatoid arthritis: long-term safety and efficacy in patients enrolled in a pilot vagus nerve stimulation study. Rheumatol. Ther. 12, 1125–1136 (2025). · DOI
  12. Peterson, D. et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron. Med. 10, 8 (2024). · DOI
  13. Levine, Y. A., Faltys, M. & Chernoff, D. Harnessing the inflammatory reflex for the treatment of inflammation-mediated diseases. Cold Spring Harb. Perspect. Med. 10, a034330 (2020). · DOI
  14. Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995). · DOI · Paper page
  15. Ostergaard, M. et al. The OMERACT rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in arthritis working group. J. Rheumatol. 44, 1706–1712 (2017). · DOI · Paper page
  16. Hofman, Z. L. M. et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?. Rheumatology (Oxford) 64, 65–73 (2025). · DOI
  17. Kay, J. et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res. Ther. 16, R40 (2014).
  18. Genovese, M. C. et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391, 2513–2524 (2018). · DOI · Paper page
  19. Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451–460 (2013). · DOI · Paper page
  20. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005). · DOI · Paper page
  21. Genovese, M. C. et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374, 1243–1252 (2016). · DOI · Paper page
  22. Gandjbakhch, F. et al. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity. J. Rheumatol. 41, 398–406 (2014). · DOI
  23. Conaghan, P. G. et al. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Res. Ther. 21, 214 (2019). · DOI
  24. Bajayo, A. et al. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc. Natl Acad. Sci. USA 109, 15455–15460 (2012). · DOI · Paper page
  25. Tamimi, A. et al. Could vagus nerve stimulation influence bone remodeling?. J. Musculoskelet. Neuronal Interact. 21, 255–262 (2021).
  26. Levine, Y. A. et al. Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis. PLoS ONE 9, e104530 (2014).
  27. Elefteriou, F. Impact of the autonomic nervous system on the skeleton. Physiol. Rev. 98, 1083–1112 (2018). · DOI · Paper page
  28. Serhan, C. N., de la Rosa, X. & Jouvene, C. Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation. J. Intern. Med. 286, 240–258 (2019). · DOI
  29. Ali, M., Yang, F., Plachokova, A. S., Jansen, J. A. & Walboomers, X. F. Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review. Eur. J. Oral. Sci. 129, e12759 (2021).
  30. Bassi, G. S. et al. Modulation of experimental arthritis by vagal sensory and central brain stimulation. Brain Behav. Immun. 64, 330–343 (2017). · DOI
  31. Rosch, G., Zaucke, F. & Jenei-Lanzl, Z. Autonomic nervous regulation of cellular processes during subchondral bone remodeling in osteoarthritis. Am. J. Physiol. Cell Physiol. 325, C365–C384 (2023). · DOI
  32. Frisell, T. et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann. Rheum. Dis. 82, 601–610 (2023). · DOI
  33. Toffa, D. H., Touma, L., El Meskine, T., Bouthillier, A. & Nguyen, D. K. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Seizure 83, 104–123 (2020). · DOI · Paper page
  34. Baker, M. C. et al. A randomized, double-blind, sham-controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis. Arthritis Rheumatol. 75, 2107–2115 (2023). · DOI
  35. Munoz Laguna, J., Lee, H., Poltavskiy, E., Kim, J. & Bang, H. Participant’s treatment guesses and adverse events in back pain trials: Nocebo in action?. Clin. Trials 21, 759–762 (2024). · DOI
  36. Bang, H., Flaherty, S. P., Kolahi, J. & Park, J. Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol. Clin. Res. Regul. Aff. 27, 42–51 (2010). · DOI · Paper page
  37. D'Haens, G. et al. Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn’s disease patients: a prospective open-label study. J. Crohns Colitis 17, 1897–1909 (2023). · DOI
  38. Baker, J. F., Conaghan, P. G., Emery, P., Baker, D. G. & Ostergaard, M. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann. Rheum. Dis. 75, 1114–1119 (2016). · doi:10.1136/annrheumdis-2014-206934
  39. Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800–802 (1988). · DOI · Paper page

Metadata

Authors
Tesser, J. R. P., Crowley, A. R., Box, E. J., June, J. P., Wickersham, P. B., Valenzuela, G. J., Gaylis, N. B., Lam, G. K. W., Pacheco, L. A., Ridley, D. J., Pinto-Patarroyo, G. P., Novack, S. N., Churchill, M. A., Kohler, M., Lee, E. C., Pando, J. A., Parris, G. R., Peterson, J. R., Shah, T., Singhal, A. K., Vuong, V., Levine, Y. A., Evangelista, M. L., Derosier, A. A., Curtis, J. R., Richardson, R. M., & Chernoff, D.
Venue
Nature Medicine
Published
2025-12-22
Volume
32
Issue
1
Pages
369-378
ISSN
  • 1078-8956
  • 1546-170X
Cited by
44
References
4
Language
en
Licence
Funders
SetPoint Medical, Inc.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. https://app.cochat.ai/papers/10.1038/s41591-025-04114-7
The paper
Tesser, J. R. P., Crowley, A. R., Box, E. J., June, J. P., Wickersham, P. B., Valenzuela, G. J., Gaylis, N. B., Lam, G. K. W., Pacheco, L. A., Ridley, D. J., Pinto-Patarroyo, G. P., Novack, S. N., Churchill, M. A., Kohler, M., Lee, E. C., Pando, J. A., Parris, G. R., Peterson, J. R., Shah, T., . . . Chernoff, D. (2026). Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-025-04114-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.